UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria

UCT943, a next generation plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria

The 2-aminopyridine MMV048 was the first drug candidate inhibiting Plasmodium phosphatidylinositol 4-kinase (PI4K), a novel drug target for malaria, to enter clinical development. In an effort to identify the next generation of PI4K inhibitors, the series was optimized to improve properties such as...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Brunschwig, C, Lawrence, N, Taylor, D, Abay, E, Njoroge, M, Basarab, GS, Le Manach, C, Paquet, T, Cabrera, D, Nchinda, AT, de Kock, C, Wiesner, L, Denti, P, Waterson, D, Blasco, B, Leroy, D, Witty, MJ, Donini, C, Duffy, J, Wittlin, S, White, KL, Charman, SA, Jiménez-Díaz, MB, Angulo-Barturen, I, Herreros, E, Gamo, FJ, Rochford, R, Mancama, D, Coetzer, TL, van der Watt, ME, Reader, J, Birkholtz, L-M, Marsh, KC, Solapure, SM, Vanaerschot, M, Fidock, DA, Fish, PV, Siegl, P, Smith, DA, Wirjanata, G, Noviyanti, R, Price, RN, Marfurt, J, Silue, KD, Street, LJ, Chibale, K
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: American Society for Microbiology 2018

Samankaltaisia teoksia

Samankaltaisia teoksia